Trial Profile
A Randomized, Open-Label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ANTHALYA
- Sponsors Roche
- 12 Sep 2017 Results (n=88) assessing prognostic value of circulating tumor cells in ovarian carcinoma presented at the 42nd European Society for Medical Oncology Congress
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 30 Nov 2016 Results assessing safety and efficacy published in the European Journal of Cancer.